适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Grindeks AS
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Clinical trial to compare availability in the body of the active substance nicotine as well as patch adhesion of the newly developed patch LTS Nicotine TTS (18.6 cm2) vs. Nicotinell® (21 mg/24 h) in healthy smokers after single patch applicatiobioequivalence and patch adhesion trialtherapeutical indication not studiedMedDRA version: 20.0Level: PTClassification code: 10057852Term: Nicotine dependence Class: 100000004873MedDRA version: 20.0Level: PTClassification code: 10053325Term: Smoking cessation therapy Class: 100000004865MedDRA version: 20.0Level: LLTClassification code: 10008374Term: Cessation of smoking Class: 10041244CTIS2023-503548-14-00TS LOHMANN Therapie-Systeme AG72
招募中
1 期
Study on the investigational drug IAMA-6, placebo-controlled, administered to healthy adult volunteers, at single oral doses and at multiple ascending oral doses to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics of IAMA-6 and its interaction with foodCTIS2023-507454-33-00Iama Therapeutics S.r.l.72
进行中（未招募）
1 期
Multicenter phase 1b/II trial testing neoadjuvant intradermal Ipilimumab and Nivolumab in high risk stage II melanoma –MARIANECTIS2023-505945-19-00Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting96
进行中（未招募）
1 期
A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing ticagrelor 90 mg hard capsules (PG402 [Celon Pharma]) vs ticagrelor 90 mg film-coated tablets (Brilique [AstraZeneca AB]) under fasting conditions in healthy volunteersPrevention of atherothrombotic events in adult patients with- acute coronary syndromes (ACS) or- a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic eventMedDRA version: 20.0Level: PTClassification code: 10028596Term: Myocardial infarction Class: 100000004849CTIS2023-504116-14-00Celon Pharma S.A.40
进行中（未招募）
1 期
A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of ABBV-383 in patients with relapsed or refractory Multiple MyelomaCTIS2023-507901-32-00AbbVie Deutschland GmbH & Co. KG55